Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses experiences with PRP, stem cell therapy, and PRF for hair growth. The original poster has used finasteride and minoxidil and is considering additional treatments for better results.

The conversation discusses using hair follicle dermal papilla exosomes for hair loss treatment. It inquires about purchasing options for this treatment.

Hair follicles are mostly dormant but can be reactivated with treatments like minoxidil, finasteride, and microneedling. A new drug, PP405, shows promise for hair regrowth but may not be available until 2027-2028.

A bodybuilder's hair transplant appears unnatural with a straight hairline and low density, possibly worsened by not using finasteride. The Turkish clinic is criticized for poor design, and the transplant may have been free for promotion.

Stem cells are being used for hair loss treatment at a Panama institute. The effectiveness of this treatment is uncertain.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

A mixture of MSM, kombucha, and black tea was applied topically for hair growth in mice. The conversation suggests skepticism about translating these results to humans.

Pyrilutamide shows minimal systemic absorption with low plasma levels and no accumulation, suggesting it's unlikely to cause systemic side effects. However, full results are not yet published in scientific journals.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

A new hair loss treatment, PP405, showed promising Phase 2a results with 31% of patients experiencing over 20% hair density increase without systemic absorption, avoiding hormonal side effects. The treatment is expected to be expensive, with Phase 3 trials starting mid-2026, and there is skepticism about the data's strength.

A user shared a 7-month update after receiving 3,153 grafts in a hair transplant, noting ongoing growth but some areas still appear sparse and red. They are in contact with the clinic for feedback and are hopeful for further improvement.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.

PP405 and JXL-069 are the same compound, but users experienced no results due to flawed application methods. The topical gel formulation of PP405 is designed to target hair follicle stem cells effectively, unlike liquid solutions that fail to penetrate deeply.

PP405 is moving to late-stage trials, showing potential for hair regrowth, with 31% of male patients experiencing a 20% increase in hair density. Veradermics is developing an oral minoxidil version, and there is interest in combining treatments for better results.

A user shared their positive experience with a hair transplant at Moart Clinic, involving approximately 10,000 grafts for a new hairline and crown. The procedure was smooth, with no pain, and the user is very satisfied with the results.

The user is pleased with the natural-looking results of their hair transplant, which used 4000 grafts at Woomchan Clinic in Seoul. The hairline appears very natural, and most people don't notice the transplant.

The user is experiencing diffuse thinning and receded hairline, using dutasteride, minoxidil, and ketoconazole without regrowth, and was prescribed clobetasol propionate 0.05% with salicylic acid for possible inflammation. Other users caution against using the strong steroid without a serious condition, sharing experiences of adverse effects and alternative treatments for scalp issues.

Hair cloning may become available in 1-2 years in Japan, but widespread availability and affordability could take 7-15 years. Current treatments like finasteride are effective but may lose effectiveness over time.

Transplanting mice skin to humans is not feasible due to immune rejection, but some suggest genetic modification or immune suppression could make it possible. Xenograft hair transplants are discouraged.

PP405, a topical treatment, shows promise for hair growth by activating inactive follicles, with 66% of participants experiencing positive results. The treatment is well-tolerated and may proceed directly to Phase 3 trials, offering a potential alternative to minoxidil and finasteride.

Oral minoxidil and spironolactone helped restore the hairline but not the scalp behind it. Hairline and temples often respond first to treatment, with mid-scalp and crown following later.

Clascosterone (CB0301) is expensive due to concentrated form and lack of market competition. Users discuss sourcing from Indian and Chinese pharmacies for cheaper alternatives, but express concerns about product quality.

A 22-year-old male with hair loss is considering treatments like finasteride, minoxidil, and derma rolling after being diagnosed with MPB, vitamin D deficiency, and dandruff. He seeks advice on whether these treatments can realistically improve his hair density and achieve a healthier NW2.

HairClone is reportedly making progress in hair cloning treatments, aiming for early access operations in the UK by 2025-2026. Users express skepticism and compare it to past efforts like Dr. Tsuji's.

A user in their early 20s is concerned about minor hair thinning and is considering a hair loss regimen involving PRP sessions, mesotherapy with dutasteride injections, and low-dose finasteride. They dislike minoxidil due to its greasiness and prefer a routine that is easy to maintain.

Hair follicle regeneration through stem cell rearrangement is discussed, focusing on bioengineered cellular structures rather than traditional hair transplants. Treatments mentioned include Minoxidil, finasteride, and RU58841.

User is seeking information on obtaining dutasteride vials for mesotherapy in the US, mentioning a closed source and lack of local clinic options.

A 26-year-old male has been treating hair loss for over three years using microneedling, minoxidil, and dutasteride, achieving good regrowth but struggling with temple hair growth. He considers reducing his minoxidil dose and possibly getting a hair transplant in the future.